In the Safety and Appropriateness of Growth Hormone Treatments in Europe (SAGhE) cohort study of > 10,000 rhGH-treated patients including approximately 1,800 CCS, conducted over 26 years in eight European countries, 37 of the 38 patients who developed meningiomas during the observation period were CCS. Here, GH1 is linked to meningioma.